Table 2.
Baseline characteristics of UKB study participants.
| All | Normolipidemic | Chylomicronemia | Hypercholesterolemia | Combined hyperlipidemia |
Remnant hypercholesterolemia |
Hypertriglyceridemia | Mixed hypertriglyceridemia and hypercholesterolemia |
|
|---|---|---|---|---|---|---|---|---|
| Number (%) | 450636 (100) | 191347 (42.5) | 63 (0.01) | 40005 (8.9) | 94785 (21.0) | 13998 (3.1) | 110389 (24.5) | 49 (0.01) |
| Demographics | ||||||||
| Age, mean (SD), y | 56.3 (8.1) | 55.0 (8.3) | 55.8 (8.6) | 58.4 (7.3) | 57.9 (7.5) | 56.8 (7.7) | 56.6 (8.1) | 52.6 (8.6) |
| Male sex, n (%) | 200353 (44.4) | 67992 (35.5) | 57 (90.5) | 14991 (37.5) | 48317 (51.0) | 4792 (34.2) | 64163 (58.1) | 41 (83.7) |
| White, n (%) | 424851 (94.3) | 179080 (93.6) | 59 (93.7) | 37725 (94.3) | 90518 (95.5) | 13408 (95.8) | 104015 (94.2) | 46 (93.9) |
| Black, n (%) | 7114 (1.6) | 4635 (2.4) | 0 (0.0) | 847 (2.1) | 635 (0.7) | 128 (0.9) | 869 (0.8) | 0 (0.0) |
| Baseline lipids | ||||||||
| TC, median (IQR), mg/dl | 225.8 (199.5-253.9) | 208.4 (186.7-229.6) | 176.4 (155.8-200.2) | 265.5 (247.1-285.7) | 267.4 (248.2-289.9) | 221.6 (197.1-247.0) | 214.5 (195.0-232.5) | 230.4 (206.8-256.5) |
| LDL-C, median (IQR), mg/dl | 143.0 (122.7-165.2) | 127.6 (111.6-142.9) | 90.5 (76.4-98.6) | 176.2 (166.0-189.5) | 178.5 (166.2-194.7) | 126.1 (109.8-143.1) | 137.2 (123.5-149.2) | 114.2 (107.0-129.6) |
| HDL-C, median (IQR), mg/dl | 54.5 (45.7-65.1) | 60.8 (51.5-71.2) | 32.7 (27.7-39.0) | 60.6 (51.9-70.7) | 49.5 (43.0-57.2) | 64.4 (54.6-74.1) | 46.9 (40.3-54.5) | 32.6 (29.5-37.4) |
| TG, median (IQR), mg/dl | 130.6 (92.3-188.9) | 90.3 (72.1-109.4) | 605.7 (512.2-696.1) | 105.1 (88.6-119.5) | 205.0 (165.5-267.6) | 179.3 (151.2-235.5) | 181.9 (153.6-232.7) | 839.3 (786.0-903.3) |
| ApoB, median (IQR), mg/dl | 107.3 (91.9-123.7) | 95.0 (83.5-106.0) | 57.4 (48.4-68.6) | 129.9 (124.2-139.7) | 135.4 (126.7-148.3) | 86.2 (75.0-97.1) | 104.7 (94.8-112.5) | 84.2 (78.4-94.3) |
| Lipid-lowering therapy | ||||||||
| Statin, n (%) | 62990 (14.0) | 15903 (8.3) | 5 (7.9) | 9984 (25.0) | 22888 (24.1) | 522 (3.7) | 13680 (12.4) | 8 (16.3) |
| Ezetimibe, n (%) | 1861 (0.4) | 437 (0.2) | 1 (1.6) | 175 (0.4) | 623 (0.6) | 33 (0.2) | 592 (0.5) | 0 (0.0) |
| Fibrate, n (%) | 1024 (0.2) | 245 (0.1) | 2 (3.2) | 57 (0.1) | 333 (0.4) | 30 (0.2) | 357 (0.3) | 0 (0.0) |
| Niacin, n (%) | 39 (0.009) | 14 (0.007) | 0 (0.0) | 1 (0.002) | 11 (0.01) | 2 (0.01) | 11 (0.01) | 0 (0.0) |
| Any therapy, n (%) | 78477 (17.4) | 22718 (11.8) | 9 (14.3) | 11393 (28.5) | 25869 (27.3) | 1054 (7.5) | 17426 (15.8) | 8 (16.3) |
| Medical history | ||||||||
| Smoking status, n (%) | 199707 (44.3) | 77564 (40.5) | 36 (57.1) | 17689 (44.2) | 46826 (49.4) | 6353 (45.4) | 51207 (46.4) | 32 (65.3) |
| Never | 248706 (55.2) | 112920 (59.0) | 27 (42.9) | 22145 (55.4) | 47466 (50.1) | 7573 (54.1) | 58559 (53.0) | 16 (32.7) |
| Previous | 152861 (33.9) | 60920 (31.8) | 27 (42.9) | 13759 (34.4) | 34631 (36.5) | 4920 (35.1) | 38581 (35.0) | 23 (46.9) |
| Current | 46846 (10.4) | 16644 (8.7) | 9 (14.3) | 3930 (9.8) | 12195 (12.9) | 1433 (10.2) | 12626 (11.4) | 9 (18.4) |
| Hypertension, n (%) | 126092 (28.0) | 41155 (21.5) | 30 (47.6) | 11699 (29.2) | 33336 (35.2) | 3573 (25.5) | 36279 (32.9) | 20 (40.8) |
| Diabetes mellitus, type 2, n (%) | 9316 (2.1) | 2624 (1.4) | 6 (9.5) | 467 (1.2) | 2366 (2.5) | 174 (1.2) | 3674 (3.3) | 5 (10.2) |
| BMI, mean (SD), kg/m 2 | 27.4 (4.8) | 25.9 (4.4) | 28.9 (3.8) | 26.9 (4.3) | 28.9 (4.5) | 26.9 (4.5) | 28.8 (4.8) | 29.3 (4.1) |
Abbreviations: apoB = apolipoprotein B; BMI = body-mass index; HDL-C = high-density lipoprotein cholesterol; IQR = interquartile range; LDL-C = low-density lipoprotein cholesterol; SD = standard deviation; TC = total cholesterol; TG = triglycerides.